Antonia DePace | Authors

Adding Lifileucel to Pembrolizumab for Immunotherapy-Naïve Melanoma Improved Responses

June 06, 2021

A higher overall response rate was noted with lifileucel and pembrolizumab versus pembrolizumab alone in patients with checkpoint inhibitor–naïve advanced melanoma, according to phase 2 trial results that were reported at the 2021 ASCO Annual Meeting.